Antiretroviral activities of NP-IDV-BMMs in HIV-1-infected hu-PBL-NOD/SCID mice. (A) Serum HIV-1p24 levels (mean ± SEM) from HIV-1-challenged hu-PBL-NOD/SCID mice untreated (control) or treated with NP-IDV-BMMs after days 7 and 14. Spleen sections from (B) untreated or (C) NP-IDV-BMM-treated mice were immunostained for CD3 (pink) and HIV-1p24 (brown). CD3⁺ T cells were observed at comparable frequencies, whereas HIV-1p24-positive cells were vastly diminished in NP-IDV-BMM-treated mice. ^*P < .05 compared with untreated controls. Magnification is (originals) ×200 and (insets) ×400. (D) Distribution of human PBLs (Vim⁺) and HIV-1-infected cells (HIV-1p24⁺) were evaluated in lymph nodes, spleen, liver, and lung from HIV-1-infected mice that were untreated or treated with NP-IDV-BMMs. Magnification is ×200.